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 Abstract 
Pre-exposure prophylaxis (PrEP), the use of antiretroviral medications by HIV-
uninfected individuals to prevent acquisition of HIV, represents a promising 
prevention option but important public health questions about PrEP remain. This 
review article updates the current evidence base for PrEP to address questions 
about effectiveness, safety and risk compensation. 
 
Daily oral FTC-TDF PrEP is highly efficacious in preventing HIV acquisition in 
individuals at risk from a range of different types of sexual exposure. There is 
good evidence of efficacy in women and men, and when men who have sex with 
men use event-based dosing. Studies have been conducted in several country 
contexts and epidemics. It is clear that adherence differs substantially and as a 
consequence there are questions about the public health benefit of PrEP.  Oral 
FTC-TDF PrEP has been shown to be extremely safe with minimal impact on 
kidney, bone or pregnancy outcomes, and to date there is no evidence that the 
effectiveness of PrEP has been diminished by risk compensation during open-
label and programmatic follow-up. It is too early to fully assess the impact of 
PrEP rollout on STI incidence at a population level. 
  
Many challenges remain.  Access to PrEP is limited and disparities exist, 
including by race and gender. Different pricing and access models for PrEP need 
to be explored to avoid further widening inequalities. The optimal combination 
prevention programme needs to be defined, and this will depend on local 









 An HIV infection in a person fully 
adherent to PrEP 
Combination 
prevention 
 Programmes that use a mix of 
biomedical, behavioural and 
structural interventions 
FTC Emtricitabine An antiretroviral used in PrEP 
2 
 
OLE Open label extension Typically a follow-on of a placebo-
controlled clinical trial, where all 
participants are given open-label 
study drug (both they and the 
investigators know the drug is 
active and not a placebo)  
PrEP Pre-exposure 
prophylaxis 
The use of antiretroviral 
medications by HIV-uninfected 




 The adjustment of behaviour in 
response to perceived changes in 
risk, in the case of PrEP, protection 
causing people to increase sexual 
behaviour that may involve 
exposure to HIV.  
Serodifferent 
partnership 
 One partner is infected with HIV 
and the other is not 
Seroconcordant 
partnership 
 Both partners are infected with HIV, 
or both partners are uninfected 
 
TasP Treatment as 
Prevention 
The public health strategy of 
treating HIV-infected individuals to 
reduce HIV incidence in the 
population 
TDF Tenofovir Disoproxil 
Fumarate 
An antiretroviral used in PrEP 
Waitlisted trial  Trial design where participants 
receive the intervention immediately 
or after a deferred period 
 
Introduction 
Pre-exposure prophylaxis (PrEP), the use of antiretroviral medications by HIV-
uninfected individuals to prevent acquisition of HIV, represents a promising 
prevention option.  
 
HIV prevention strategies that include both targeted and broad ‘test and treat’ 
interventions have not had the predicted impact on the HIV epidemic (1).  
Modelling studies suggest that PrEP has the potential to curtail the HIV epidemic 
when used as part of a combination public health prevention strategy(2-4).  The 
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estimated number needed to treat to prevent one new infection might be as low 
as 13 when PrEP is given to a group at high risk of HIV (e.g. incidence up to 
9%)(5).  Effectiveness studies and open label extension demonstration projects 
in both high and low income settings have shown that PrEP can be delivered 
feasibly within existing health systems.  However, uptake, reimbursement 
packages and provision of PrEP currently vary from country to country, where 
national PrEP programmes have been established. 
 
Early data from San Francisco suggest that roll-out of PrEP, in combination with 
other strategies, has been associated with a decline in HIV incidence despite 
slow initial uptake(6).  By the end of 2016, it was estimated that 30% of the city’s 
gay and bisexual men were using PrEP as part of the ‘Getting to Zero’ initiative 
that incorporates PrEP, rapid linkage to care and initiation of antiretrovirals, and 
retention and re-engagement of HIV-positive people in care(7, 8).  A decline in 
HIV diagnoses has also been reported in five sexual health clinics in London, 
attributed to a combination of early testing, early access to antiretrovirals 
including as Treatment as Prevention (TasP) and PrEP sourced through private 
or trial means (9-11). 
 
It has been established that PrEP adherence is probably the strongest 
determinant of PrEP effectiveness in trial settings. How to optimize adherence 
outside of a clinical trial is not well understood and is likely to differ by country, 
culture and population group.  Important ethical issues also exist, including how 
to ensure access to PrEP for everyone who will benefit.  This is a particular issue 
for at-risk, marginalized populations such as Black, Asian and Minority Ethnic 
(BAME) groups.  Finally, PrEP as an intervention sits within a complex social 
structure, and careful thought about how risk-perception should be 
conceptualised and presented to ensure those who may benefit from PrEP can 
access it without contributing to or causing stigma. 
 
This review updates the current evidence base for PrEP to address questions 
about effectiveness, safety and risk compensation. In doing so, it provides an 
overview of adherence, adverse events, risk behaviours, breakthrough infections 
and the cost-effectiveness of PrEP.  National and international guidelines are 
detailed and an overview of alternative drug regimens is provided.    
 
Incidence/prevalence 
In 2016, there were an estimated 36.7 million (30.8 million- 42.9 million) adults 
and children living with  HIV in the world, with a prevalence of 0.8 (0.7-0.9) 
among adults aged 15 to 49.  An estimated 1.8 million (1.6-2.1 million) people 
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globally became newly infected with HIV in 2016(12)  giving an incidence of 0.43 
per 1,000 population (adults 15-49), and the number dying was 1.0 million (0.83-
1.2 million). 
 
Data on the uptake of PrEP within PrEP programmes are available through 
prescription data and health service data.  In the United States, an analysis of 
electronic prescription data from approximately 80% of retail pharmacies 
between 2012-2016 by Gilead (manufacturer of Truvada) found that 98,732 
people started PrEP during this period and estimated that 136,000 people in the 
US were on PrEP by the end of the second quarter of 2017.  These data do not 
include non-retail pharmacy prescriptions, such as private PrEP or national 
Medicaid programmes. Uptake of PrEP was characterized by a period of slow  
initial uptake, followed by an acceleration and then a steady state(13).  Data from 
the cross-sectional National HIV Behavioural Surveillance (NHBS) System found 
that only 4% of surveyed MSM reported using PrEP,  but more than half  
reported that they  would be willing to take it(14). A PrEP programme in New 
South Wales in Australia has enrolled over 6,500 participants over a 70 week 
period with steady enrollment(15). In France, 2805 people had started on PrEP in 
the first year of the programme(16). Data are emerging on uptake from other 
national PrEP programmes. 
 
Methods 
This review extends the comprehensive systematic literature review and meta-
analysis conducted by Fonner et al(17) that included all literature on PrEP 
published in peer-reviewed journals or presented at a scientific conference 
between 1 January 1990 and 15 April 2015.  Key outcomes included HIV 
infection, adverse events, antiretroviral drug resistance, including effectiveness of 
hormonal contraception with PrEP and effects on pregnancy, and sexual 
behaviour.  To be included in the Fonner review, studies had to be a randomized 
controlled trial (RCT), an open label extension (OLE), or a demonstration project 
evaluating oral PrEP containing TDF to prevent HIV infection and measure one 
or more key outcomes, comparing those randomized to PrEP vs placebo or no 
PrEP use.    
 
We replicated the methodology, including the search terms, used by Fonner et al 
although the search and data extraction were performed by one person instead 
of two.  We included studies published in peer-reviewed journals or presented at 
a scientific conference between 16 April 2015 and 19 September 2016.  Only 
English language and human studies were included. The following databases 
were searched: PubMed, Embase, and CINAHL (Cumulative Index to Nursing 
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and Allied Health Literature). For conference abstracts, the Database of Citations 
Index was searched.  Iterative secondary reference searching on all included 
studies was also conducted.   
 
In addition to the data extracted in the Fonner review, and updated here, this 
review extracted data on cost-effectiveness and breakthrough infections.   
 
Results of evidence review 
The Fonner review screened 3,068 citations.  39 articles and six conference 
abstracts describing 18 PrEP-related studies were included in the review.  15 of 
these were RCTs and three were observational OLE or demonstration projects.  
Seven RCTs were double-blinded, placebo-controlled trials of daily oral PrEP, 
two studies randomized participants to immediate or delayed PrEP and one 
study compared daily PrEP with placebo and ‘no pills’.  
 
In the extended literature review of articles published between April 2015 and 
September 2016, a further 1,271 citations were screened.  Eight articles and two 
conference abstracts covering further data on six of the studies identified in the 
Fonner review were included (fig 1). This extended literature review provides full 
results of the PROUD(18, 19) and IPERGAY studies(20, 21), additional safety 
data from the iPrEx(22), Partners PrEP(23, 24) and VOICE(25) studies, and 
updated sexual behaviour data from the IPERGAY study(21). 
 





Recent evidence for PrEP 
Overview of evidence of efficacy of PrEP 
The review by Fonner et al showed that oral PrEP containing TDF-based 
regimens are highly effective in preventing the transmission of sexually acquired 
HIV infection across different risk groups (17).  The meta-analysis of 11 RCTs 
that compared PrEP with placebo estimated a 51% reduction in risk of HIV 
infection comparing PrEP with placebo (risk ratio=0.49, 95% CI 0.33-0.73) in the 
intention to treat analysis; all randomized participants were included regardless 
of adherence except those who were acutely HIV infected at baseline. 
Adherence, indicated by the proportion in the active arms who had any 
detectable PrEP medications in blood, was strongly associated with PrEP 
effectiveness between trials. PrEP effectiveness did not depend on gender, route 
of exposure (penile/vaginal vs anal), or age.   
 
MSM 
Evidence from high-quality placebo-controlled RCTs, an open-label RCT comparing 
PrEP to no-PrEP and open-label extensions (OLE) demonstrate the high level of 
efficacy and effectiveness of TDF-FTC PrEP for MSM. Meta-analysis suggests that the 
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reduction in HIV transmission comparing PrEP with placebo for rectal exposure is 0.34 
(95%CI 0.15-0.80, p=0.01) (17). However, with high adherence this risk reduction is 
likely greater.  Few data exist for trans-populations, though several of the studies 
described below included trans-men and women. Of note, there was only one small 
study of PrEP using TDF-alone for MSM which showed no infections after receiving 
active PrEP, and six emergent infections in the placebo arm and deferred phases of the 
study(26)   
 
One Phase 3 placebo-controlled RCT has assessed the efficacy of daily PrEP 
(iPrEx) (27), one Phase 3 open-label RCT has evaluated the effectiveness of 
daily PrEP compared to no-PrEP (PROUD) (18)and one Phase 3 placebo-
controlled RCT has evaluated the efficacy of ‘on demand’ PrEP (IPERGAY) 
among MSM (28). 
 
The largest study of daily oral PrEP among MSM is the iPrEx study(27).  This 
was a high-quality phase 3, randomized, double-blinded, placebo-controlled 
multi-centre trial conducted among 2499 MSM and trans-gender male-to-female 
adults in Peru, Ecuador, Brazil, Thailand, South Africa and the United States.  
Participants were randomly assigned to either a daily dose of FTC-TDF (1251 
participants) or placebo (1248 participants). Participants were followed up every 
four weeks with interview, HIV testing, risk-reduction counselling, adherence, pill 
count and dispensing of pills and condoms for a total of 3324 person-years. The 
primary outcome was HIV infection. 100 participants became infected with HIV 
over the course of the study; 36 in the FTC-TDF group and 64 in the placebo 
group, representing a 44% (95% CI 15-63) reduction in HIV incidence using a 
modified intention to treat (mITT) analysis. After adjustment for age difference 
between the two groups, the efficacy was estimated to be 43% (95% CI 14-62).  
 
 
The first study to explore the real-world effectiveness of daily oral PrEP among 
MSM was the PROUD study(18), full results of which were published after the 
Fonner review.  This was a Phase 3, randomized, open-label waitlisted trial 
conducted among 544 HIV-negative MSM at 13 sexual health clinics in England.  
Participants were randomly assigned to either receiving a daily dose of FTC-TDF 
immediately (275 participants), or after a deferral period of 12 months (269 
participants). Participants were followed up every three months with an HIV test 
and screening for sexually transmitted infections (STIs). Following an interim 
analysis, the study was halted early and all participants who were still in the 
deferral period were offered study drug. A total of 243-person years follow-up in 
the immediate group and 222-person years follow-up in the deferred group had 
8 
 
accumulated. 23 participants were infected with HIV during the period of 
randomized trial observation; three in the FTC-TDF group and 20 in the deferred 
(no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 
person years (90% CI 4.3- 11.3) in the modified ITT analysis and a relative risk 
reduction of 86% (90% CI 64%- 96%).  The number needed to treat over one 
year was 13 (90% CI 9-23).  HIV incidence in the no-PrEP group was 9 per 100 
person years compared to 1.2 per 100 person years in the PrEP group.  HIV 
incidence in the no-PrEP group was markedly higher than that seen in the MSM 
population attending sexual health clinics in England, showing that the study had 
recruited a group at especially high risk of HIV infection(29). 
 
The third trial to show a significant reduction in HIV infections with PrEP was the 
Phase 3, randomized, placebo-controlled multi-centre IPERGAY trial of PrEP for 
MSM which evaluated an event-based oral TDF/FTC regimen compared to 
placebo. Full results were published after the Fonner review. 414 participants 
were randomly assigned to either receiving an ‘on demand’ regimen of Truvada 
or placebo(28). The ‘on demand’ regimen involved taking two pills (2 x 300mg 
TDF/2 x 200 mg FTC) 2-24 hours before sex, and continuing with a daily pill 
during periods of sexual risk, followed by post-exposure pills 24 hours and 48 
hours after the last sexual exposure. The study was unblinded at interim review 
due to high efficacy of the drug that conferred a relative risk reduction of 86% 
(95% ci 40%-98%).  
 
There has been one phase 2 safety trial, the CDC MSM Safety Trial(26) that 
compared TDF to placebo in a randomized, double-blinded, placebo-controlled 
waitlisted trial among 400 HIV negative MSM.  Participants were randomised in a 
1:1:1:1 design to receive TDF or placebo immediately or after nine months.  Main 
end points were safety and behavioural effects.  No adverse events were 
associated with tenofovir PrEP and there was no evidence of risk compensation. 
Participants were followed up with interview, an HIV test and screening for STIs, 
risk reduction and adherence counselling every three months for 24 months. 
There were no infections among those taking active drug.  Seven participants 
seroconverted: four in the placebo arm and three among delayed arm 
participants who were not on study drug.  One participant in the placebo group 
was HIV infected at enrollment. 
 
There have been two smaller studies.  The first was a feasibility and acceptability 
pilot study; Project PrEPare recruited 58 MSM aged 18-22 in the United States.  
Participants were randomized to receiving a behavioural intervention alone, the 
behavioural intervention + PrEP or the behavioural intervention + placebo.  There 
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were no seroconversions among the 58 participants(30). The study 
demonstrated the feasibility of enrolling young MSM, in particular young BAME 
MSM who have a disproportionately high risk of HIV. Retention in the study was 
98%.  However, self-reported and drug-level based adherence was low, 
suggesting low acceptability of the drug intervention.  
 
The second was the IAVI Kenya Study, a small safety and adherence study 
conducted among Kenyan MSM and female commercial sex workers (CSW).  67 
MSM and five female CSW were randomized to receive daily FTC-TDF or 
placebo, or intermittent FTC-TDF or placebo in a 2:1:2:1 ratio.  There was one 
seroconversion in the placebo arm(31).   
 
The iPrEx Open Label Extension (iPrEx-OLE)(32) enrolled 1603 HIV-negative 
men and transgender women who have sex with men who were previously part 
of PrEP studies (iPrEx, ATN082/Project PrEPare and US Safety study).   
Participants were enrolled into the study whether or not they chose to take up 
PrEP.  Participants were followed up for 72 weeks after enrollment into the open-
label extension.  76% of those enrolled in the open-label extension initiated 
PrEP, and this was higher among those reporting condomless receptive anal 
intercourse and those who were herpes simplex-2 virus seropositive. The 
majority of participants at risk of HIV and choosing to use PrEP; defined by 
condomless receptive anal intercourse, more than one anal intercourse partner, 
recent STI (syphilis, gonorrhea or chlamydia diagnosed at that visit); returned for 
PrEP at 12 weeks, suggesting use during periods of risk.  
 
As during the randomized phase of the iPrEx study, there were no 
seroconversions in the open label extension among participants with protective 
drug levels in dried blood spots (taken quarterly), which was associated with 
taking 4-7 tablets per week.  Retention in the study was not associated with 
sexual risk behaviour. Overall reduction in HIV incidence compared to the group 
who did not take up PrEP in the OLE was non-significant at 49% (95% CI -1 to 
74%) after adjusting for sexual behaviour, but was significantly lower than the 
placebo group in iPrEx (51% reduction in HIV incidence, 95% CI 23% to 
69%)(32).  
 
The IPERGAY OLE enrolled 333 existing PrEP users and 29 new patients and 
followed them for 18.4 months (IQR 17.5-19.1).  The study demonstrated a 
marked reduction of 97% in HIV incidence in the PrEP group from the trial and 
OLE combined (three infections in 734 patient-years of follow up) compared to 
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the placebo arm of the IPERGAY study (14 infections in 212 patient-years of 
follow up)(20).   
  
Transgender women 
iPrEx is the only study to date to report findings in transgender women, albeit in 
small numbers and without demonstrating evidence of an effect in HIV prevention 
in this group.  Of the 2499 participants in iPrEx, 399 (14%) were classified as 
trans-gender women.  Among transgender women, there were 11 HIV infections 
in the PrEP group and ten in the placebo group (hazard ratio 1.1, 95% CI 0.5-
2.7)(33); the trend toward lower effectiveness among trans women corresponded 
to lower rates of drug detection, especially among transgender women reporting 
higher risk behaviour.  
 
During the iPrEx open label extension, 192 transgender women enrolled and 
were eligible to take PrEP; 151 (79%) chose to take PrEP(33).  There were three 
seroconversions among transgender women with drug levels equivalent to less 
than two pills per week, below the level of quantification or were off PrEP.  No 
seroconversions were seen among transgender women with drug levels 
equivalent to 2-3 pills per week or greater.  There were lower drug concentrations 
among transgender women using feminizing hormones compared to other 
transgender women and could reflect lower PrEP adherence.  
 
Although ex-vivo studies in  women have suggested that hormone treatments 
can have a role in increasing susceptibility to HIV infection by altering 
intracellular tenofovir concentrations(34), this is a theoretical concern and 
evidence from studies of antiretroviral interactions with hormonal contraceptives 
has been reassuring(35). However, there have been no pharmacological 
interaction studies done in transgender women using both PrEP and hormones.  
Furthermore, PrEP studies that have included transgender women have not been 




PrEP efficacy among heterosexual populations has been explored in two Phase 
3 randomised controlled trials in high-risk heterosexual women (FEM-PrEP, TDF-
2, VOICE)(36, 37), one Phase 3 RCT comparing daily PrEP with placebo among 
sero-discordant couples (Partners PrEP) (38) , and one OLE of daily PrEP 
(Partners Demonstration Project) (39) These studies demonstrated a high level 
of efficacy of tenofovir-based PrEP in reducing the risk of HIV transmission in 
heterosexual populations where adherence to drug was high.  The meta-analysis 
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by Fonner et al estimated the relative risk for HIV infection comparing PrEP with 
placebo for penile/vaginal exposure to be 0.54 (95% CI 0.32-0.90; p=0.02) (17).  
 
No studies have evaluated the efficacy of an event-based or intermittent PrEP 
regimen in heterosexuals and to date there are no heterosexual RCT studies 
undertaken in high-income countries. While there is no reason to doubt that the 
biology of transmission is the same worldwide, the trials to date have clearly 
demonstrated that adherence data cannot be extrapolated from one population to 
another.   
 
The strongest evidence of effectiveness among serodiscordant heterosexual 
couples was reported in the large multi-country Partners PrEP study among 
serodiscordant couples(38). This double-blinded Phase 3 RCT randomized and 
followed 4747 couples to single (TDF alone) or dual agent (TDF co-formulated 
with FTC) PrEP or placebo. The study provides evidence of clinical efficacy for 
daily FTC-TDF (75% (95% CI 55%-87%) or TDF (67% (95% CI 44%-81%) 
among serodiscordant opposite gender couples in sub-Saharan Africa.  No 
significant difference was observed between FTC-TDF and TDF (p=0.23). 
Although the placebo arm of this study was stopped earlier than anticipated, the 
finding of no difference between FTC-TDF and TDF was replicated in the 
Partners PrEP open-label extension demonstration project.   
 
In the TDF-2 study, 1219 men and women at high risk of HIV in Botswana were 
randomized to daily oral FTC-TDF or placebo(40). The study provided good 
evidence for efficacy of PrEP (62%; 95% CI 16%-83%; p=0.03).  However, one 
third of participants did not complete follow up per protocol and 10% were lost of 
follow-up resulting in risk of bias. 
 
Two studies, FEM-PrEP(36) and VOICE(37), demonstrated no benefit of PrEP 
among heterosexual women at risk of HIV infection, which is considered due to 
poor adherence to study medication.  FEM-PrEP was a phase 3 double-blinded 
RCT conducted in sub-Saharan Africa that randomized 2120 heterosexual 
women at high risk of HIV to daily oral FTC-TDF or placebo.  There was no 
evidence for the clinical efficacy of daily oral FTC-TDF (HR=0.94; 95% CI 0.59-
1.52) for heterosexual women.  However, there was very low adherence to the 
study drug in the intervention arm; less than 40% of HIV uninfected women had 
drug measured in plasma, despite high self-reported adherence.   Among the 
women who seroconverted in the intervention arm, drug levels in blood indicated 




The VOICE study randomized 5029 women at high risk of HIV infection in sub-
Saharan Africa in a Phase 2b double-blinded RCT to oral TDF, oral FTC-TDF, 
vaginal tenofovir gel or placebo(37).  The VOICE study provided no evidence of 
clinical efficacy for daily FTC-TDF (HR 1.04; 95% CI 0.73-1.49) or TDF (HR 1.49; 
95% CI 0.97-2.29) for heterosexual women.  Again, despite high self-reported 
adherence, study drug was only detected in 30% of those randomized to taking 
oral drug.   
   
People who inject drugs 
 
The only placebo controlled trial of PrEP among PWID randomized 2413 
participants in Thailand to receive daily oral TDF or placebo(42).  There was a 
48.9% reduction in HIV incidence in the PrEP group (95% CI 9.6-72.2; p=0.01) 
with greater efficacy seen in women compared to men (78.6 per 100py (95% CI 
16.8-96.7; p=0.03 in women compared to 37.6 (95% CI -17.8 to 67.9; p=0.15) in 
men).  Efficacy was associated with older age (88.9%, 95% CI 41.1 to 99.4; 
p=0.01) in those aged >40 compared to 33.6% (95% CI -40.1 to 69.8; p=0.30) in 
those aged 20-29). Reports of needle sharing was a risk factor of HIV acquisition, 
and most study participants reported sexual activity that could have exposed 
them to HIV.  The trial sites did not provide access to clean injection equipment 
which is considered to be the standard of care. PrEP use was directly observed 





Black Asian and Minority Ethnic (BAME) populations, particularly MSM, are at 
increased risk of HIV infection in higher income countries. There are limited data 
on the efficacy of PrEP in BAME populations and studies are underway to offer 
PrEP and provide adherence support. In the iPrEx study, a sub-analysis of 
efficacy of PrEP in Hispanic (N=900 on PrEP, N=901 on placebo) versus non-
Hispanic participants (N=351 on PrEP, N=342 on placebo) found no difference in 
efficacy (HR 0.48 (95%CI 0.14-1.60) in Non-Hispanic versus HR 0.57 (95% CI 
0.37-0.89); p=0.79) (27).  In the PROUD study, the majority of participants were 
of white ethnicity (81%) but no data are available on efficacy by ethnicity, 
similarly for the IPERGAY study. 
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Table 1: Summary table of included studies for effectiveness of oral HIV preexposure prophylaxis for all populations 






PrEP dosing and 
comparison 
Primary 










PrEP (95% CI) by 
MITT* 









Daily PrEP to 
placebo 
Rectal MSMc and 
transgender 
women 
2499 44% (15-63%) 







FTC/TDF Daily PrEP to no 
PrEP use 
Rectal MSM and 
transgender 
women 
1603 49% (-0.1-74%) 
PROUD(18) RCT England FTC/TDF Immediate to 
delayed PrEP 
Rectal MSM 545 86% (64-96%)e 
 
Project PrEPare(30) RCT USA FTC/TDF Daily PrEP to 
placebo and to ‘no 
pill’ 
Rectal Young MSM 58 No seroconversions 
IPERGAY(28) RCT France, 
Canada 
FTC/TDF Intermittent PrEP 
to placebo 
Rectal MSM 400 86% (40-99%) 
IPERGAY OLE(20) Cohort France, 
Canada 
FTC/TDF Intermittent PrEP 
to placebo 
Rectal MSM 362 97% (81-100%) 
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Rectal MSM and 
FSW 




RCT USA TDF Immediate/delaye
d PrEP to 
immediate/delaye
d placebo 
Rectal MSM 400 7 seroconversions (4 




RCT S Africa, 
Thailand, 
USA 
FTC/TDF Daily, time and 





500 12 infections, 
distributed across 
the arms  
Bangkok Tenofovir 
Study(42) 
RCT Thailand TDF Daily PrEP to 
placebo 
Vaginal/penile People who 
inject drugs 
2413 48.9% (9.6-72.2%) 
Bangkok Tenofovir 
Study OLE(46) 
Cohort Thailand TDF Daily PrEP to 
placebo 
Vaginal/penile People who 
inject drugs 
787 All: 48.9% (9.6-72.2) 
Females: 78.6 (16.8-
96.7) 













All: TDF/FTC: 75% 
(55-87%) 
TDF: 67% (44-81%) 
Women: TDF/FTC: 
66% (28-84%) 
TDF: 71% (37-87%) 
Men: TDF/FTC: 84% 
(54-94%) 





















FTC/TDF Daily PrEP to 
placebo 
Vaginal/penile Heteroseuxa
l men and 
women 
1219 61.7% (15.9-82.6%) 
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FTC/TDF Daily PrEP to 
placebo 
Vaginal/penile Women 2056 6% (-52-41%) 









 Daily PrEP to 
placebo 
Vaginal/penile Women 4969 TDF/FTC: -4.4% (-
50-27%) 
TDF: -49%  
(-130-3%) 





TDF Daily PrEP to 
placbeo 
Vaginal/penile Women 936 65% (-93-97%) 
a. RCT: Randomized controlled trial 
b. FTC: Emtricitabine; TDF: tenofovir disoproxil fumarate 
c. MSM: men who have sex with men 
d. OLE: open label extension  
e. 90% confidence interval from the PROUD study 
 












PrEP effectiveness is strongly associated with adherence. Measures of 
adherence vary in studies, and include self-report, pill count and drug 
concentrations.  Drug concentrations can be measured in red blood cells (RBCs)  
and peripheral blood mononuclear cells (PMBCs).  The median half-life of 
tenofovir-diphosphate, an active form of the drug, is 17.1 days (interquartile 
range 15.7-20.2) in red blood cells and 4.2 (3.7-5.2) days in PBMCs. Therefore, 
estimates of both recent and cumulative drug exposure can be generated. Dried 
blood spots, which contain millions of RBC can be used as a convenient 
sampling method to quantify adherence(49). 
 
The amount of adherence required for drug detection varies depending on the 
assays used; in most, use of one or two PrEP tablets per week was sufficient for 
drug to be detected in blood.  Using definitions outlined in the Fonner review 
‘high adherence’ was defined as the proportion of those receiving drug with 
detectable drug levels >70%, ‘moderate adherence’ as 41-70% and ‘low’ as  40% 
or less. Studies such as FEM-PrEP and VOICE had <30% drug detection overall, 
an adherence level that conferred no HIV protection.  Studies such as Partners 
PrEP (FTC/TDF arm) where over 80% of blood samples had drug detected 
demonstrated correspondingly high levels of efficacy.  In all studies, in the subset 
of participants with detectable drug, HIV risk reduction ranged between 70-92%, 
and risk reduction among MSM was 99% (95% CI 96 to 100%) among MSM 
whose drug concentrations were commensurate with daily use(50).  
 
Figure 2 demonstrates the close relationship between drug levels and 
effectiveness. 
 
Fig 2: Fitted meta-regression line of the relationship between trial-level PrEP 








Alternative drug regimens 
Reducing the number of tablets taken might lead to more cost-effective use of 
PrEP if this can be achieved without a loss of HIV prevention activity. Grant et 
al(51) have described that some MSM have variable periods of higher risk of HIV, 
and they are inclined to take PrEP more intensively during such periods.  Such 
strategic use periodic use of PrEP may increase impact and lower the overall 
cost to the health system.  
 
Data extrapolated from RCTs(18, 27, 28) and pharmacokinetic studies(52) 
suggest that intermittent dosing with at least four tablets per week, or event-
based dosing with two tablets 24 hours before and one tablet 24 hours after and 
48 hours after sex is protective against HIV acquisition during anal sex.  There is 
no evidence to date for these regimens in insertive or receptive vaginal sex.  
 
Concerns have been raised that less than daily dosing might result in lower 
adherence to drug. However, this has not been borne out by drug level 
measurements in the first 113 participants receiving PrEP in the IPERGAY study, 
where high levels of TDF and FTC were detected (86% and 82% respectively). 
The efficacy of on-demand PrEP in the IPERGAY study however was in the 
context of participants using a median number of 15 pills/month and having 10 
sexual intercourse per month. Among the subset of 269 participants using ≤15 
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pills per month systematically or often during sexual intercourse, and contributing 
to 134 person years of follow-up, there were 6 HIV infections all in the placebo 
group (incidence 9.3 (95%CI 3.4-20.1) per 100py) with a relative rate reduction of 
100% (95% CI 39-100%; 0.013)(53).  
 
PrEP ‘failures’: Breakthrough infections 
HIV infections among individuals receiving PrEP during trials were attributed to 
undiagnosed HIV infection at the time of starting PrEP, or infections during 
periods of no or low PrEP use as indicated by no or low drug concentrations in 
blood. Rare breakthrough infections appear to have occurred in clinical practice, 
possibly due to exposure to a multi-drug resistant HIV or an overwhelming 
inoculation of virus, although such cases from clinical practice are never as well 
characterized as in clinical trials. 
 
Two multi-class, drug resistant, apparent breakthrough HIV infections have been 
described. Importantly, clinical and pharmacokinetic data in these cases 
suggested good long-term adherence to FTC-TDF by the patients (54, 55), 
although the drug concentrations were measured several weeks after the 
patients switched from PrEP to fully suppressive antiretroviral therapy. One case 
was not tested for HIV in the 2 months prior to starting PrEP (usual standards 
require HIV testing within 7 days).  The other case had missed all of his follow-up 
appointments after receiving a PrEP prescription.   More recently, a PrEP 
breakthrough infection with wild-type virus was reported from the AmPrEP study 
in a participant with high self-reported adherence and high drug levels detected 
on dried blood spot testing(56).  This participant’s viral load was undetectable 
while on PrEP; the rising viral load several weeks after stopping PrEP raised 
questions about the timing of infection because of viral suppression whilst on 
PrEP.  Also, drug resistance testing performed after therapy is stopped, as was 
done in this case, can be falsely negative due to overgrowth of drug sensitive 
strains(57).  
 
A particular problem for HIV infections that are undiagnosed at the time of 
starting PrEP is that the drug may drive de novo resistance mutations, 
particularly where drug adherence is poor and drug levels fluctuate. Fonner et al 
reviewed results from six trials that reported cases of FTC or TDF drug 
resistance using standardized genotypic laboratory assays(17). The risk of 
developing an FTC-related mutation among those acutely infected with HIV at 
enrollment was significantly higher in the group randomized to receive FTC/TDF 
PrEP compared to placebo (risk ratio=3.72, 95% CI 1.23- 11.23, p=0.02).  The 
risk of a TDF-related mutation was not statistically different between PrEP and 
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placebo regardless of PrEP regimen among those acutely infected at enrollment.  
Additionally, six (2%) TDF or FTC-resistant infections occurred among 544 
postrandomisation HIV infections; five in PrEP groups and one in a placebo 
group. Numbers were too small to calculate a pooled relative risk.  
 
These cases highlight the importance of systematic monitoring and surveillance 
of PrEP use and breakthrough infections at a population level. 
 
Adverse events 
To date, studies of TDF-FTC PrEP provide robust evidence of safety with short-
term use (2-3 years). The metanalysis by Fonner et al(17) demonstrated no 
difference in the proportion of adverse events comparing PrEP to placebo across 
10 placebo-controlled RCTs (OR 1.01, 95% CI 0.99- 1.03, p=0.27), with no 
differences seen in subgroup analysis that included mode of acquisition, 
adherence, gender, drug regimen, dosing or age.  No differences were seen in 
grade 3 or 4 adverse events comparing PrEP and placebo groups across 11 
placebo-controlled RCTs (Risk ratio= 1.02, 95% CI 0.92-1.13, p=0.76).  Results 
were not presented by sub-group.  
 
The commonest side effects reported in studies were gastrointestinal(28, 40), 
headache(18), and nausea(18, 40).  Depression was commonly reported yet the 
rates did not differ in the placebo and active arms (27). Of note, gastrointestinal 
events were more commonly reported in the PrEP group in the IPERGAY study 
compared to placebo (14% vs 5%; p=0.002), but no such differences were found 
in the meta-analysis. 
 
Use of TDF-FTC as PrEP has been associated with a mild non-progressive 
decline in creatinine clearance(24, 27, 28, 37, 40, 58) that is reversible on 
discontinuation of drug(27, 58).  
 
An association between decline in bone mineral density (BMD) and FTC-TDF 
PrEP use has also been documented(22, 25, 40, 59), but no evidence has been 
found of an associated increase in fracture risk.  The change in BMD occurred by 
week 24, did not progress with additional PrEP use, and recovered to levels 
observed in the placebo arm after stopping PrEP(60, 61). 
 
Risk behaviour 
It has been proposed that PrEP might lead to risk compensation, whereby people 
taking PrEP might have higher risk sexual behavior because the risk of HIV 
infection is no longer felt to be relevant. Such a behavior change might increase 
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the risk of other STIs, particularly among groups that already have 
disproportionately high incidence of STIs such as MSM. Studies have 
investigated the possibility of risk compensation by collecting information about 
reported condom use and partner numbers and using diagnosed STIs as an 
objective measurement of risk  
 
However, studies exploring risk compensation are difficult to design as self-
reported behavioural data are subject to reporting bias, may vary inter-and intra-
individuals and reporting may vary across the study period. STI incidence used 
as a marker of risk compensation may be affected by increased testing frequency 
in the study, the types of tests used (e.g. use of dual tests for chlamydia and 
gonorrhoea may increase detection rates of gonorrhoea), changes in background 
population-level STI incidence and other simultaneous interventions such as 
health promotion messages(62).  Therefore, monitoring of behavioural and 
biological markers of risk compensation is important, but inferring associations at 
population level between use of PrEP and increased risk behaviour is fraught 
with difficulty in the context of general increases in risk behaviours(63) and 
increases in STIs(64).   
 
Data are available from RCTs of PrEP, though these were not powered to detect 
differences in sexual risk or STIs. Furthermore, participants in RCTs do not know 
whether they are taking active drug and so there is no expectation that they will 
modify their behaviour in the same way that would happen in the real world. As 
such, RCTs only provide limited evidence about risk compensation that is 
generalisable to wider use of PrEP.  Fonner et al(17) found no difference in 
condom use or partner numbers between study arms, and no change or only 
small increases in condom use and decrease in partners over time among the 
RCTs of MSM, heterosexuals and PWIDs. However, meta-analysis was not 
possible due to heterogeneity of the studies. The IAVI Kenya study, which 
included MSM, was the only trial to report an increase in sexual partners from 
baseline to follow-up (from 3 at baseline to 4 at month 4), but partners may have 
been underreported at baseline(31).   
 
Open-label studies and demonstration projects, whose results were published 
after the Fonner review, provide better evidence regarding risk compensation 
because patients know whether they are taking drug and the patients will often 
be aware of the effectiveness of PrEP in preventing HIV infection. Risk 
compensation may be more likely in this instance.  However, the data are 
conflicting. On the one hand, a number of studies suggest no evidence of risk 
compensation. The PROUD study showed no difference between the immediate 
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and deferred (no-PrEP) groups in the total number of sexual partners (p=0.57) at 
1 year or in the frequency of overall bacterial STIs (p=0.74)(65).  However, a 
greater proportion of the immediate group reported receptive anal sex without a 
condom with ten or more partners at one year compared to the deferred group 
(21% vs 12%, p=0.03). The Partners PrEP demonstration follow-up project, 
reported condomless sex acts in the main partnership decreased compared to 
the RCT phase, but there was a slight increase in condomless sex acts outside 
the main partnership. Nevertheless, rates of STIs and pregnancy did not 
change(66). In iPrEx OLE, self-reported risk behaviours including number of 
partners and condomless sex declined over the period of the study.  Incidence of 
syphilis was similar among those taking PrEP and those who were not(32). Data 
from San Francisco’s demonstration project also suggests no increase in risk 
behaviours or STIs(67, 68).   On the other hand, early data from the Australian 
Victorian PrEP Demonstration Project, although outside of the search period for 
this review, suggests an increase in risk compensation. Over the first 12 months 
of the study, self-reported condom use declined concomitantly with a significant 
increase in incidence of STIs from 43.2 per 100py at months 0-3 to 119.8 per 
100py at months 3-12 (incidence rate ratio 2.77 (95%CI 1.52-5.56))(69). 
However, the study had a small sample size of 114 and data on STI rates prior to 
study entry were not available.  Similar increases in STI rates were reported in 
the US-based Kaiser cohort of PrEP users (although also outside of the search 
period for this review); over the first year, rectal chlamydia positivity increased 
from 0.9% to 2.5% (p=0.012) and urethral gonorrhoea positivity increased from 
7.7% to 14.1% (p<0.001), and data from Seattle demonstrate a decline in 
condom use and increase in STI diagnoses after PrEP initiation(70).(70)  
 
Overall, these studies are difficult to interpret because the observations might be 
explained by a range of factors, including changing risk behaviour, increased 
detection of STIs due to more screening, or unrelated changes in STI 
transmission dynamics in the wider population. However, to date, it remains the 
case that no large increases in STI incidence have been attributed to PrEP, and  
PrEP may create opportunities for STI testing and counselling, and for 
contemplation of sexual goals and risks, which might mitigate risk compensation 
(71). 
 
Pregnancy, contraception and PrEP 
FEM-PrEP and Partners PrEP investigated the effectiveness of oral 
contraception and PrEP when taken simultaneously to investigate whether one 
might affect the other. The evidence to date suggests that PrEP does not affect 
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the effectiveness of injectable contraception(72) and injectable contraception 
does not affect oral PrEP efficacy(73), though numbers are small.  
 
Data indicate that oral PrEP does not have an adverse impact on fertility or 
pregnancies(74).  431 pregnancies occurred in the Partners PrEP study with no 
difference in pregnancy incidence, loss, preterm birth, congenital abnormalities or 
intrauterine? growth between the study arms.  However, PrEP was discontinued 
on detection of pregnancy, and therefore data on the safety of TDF-FTC in HIV 
positive pregnant women may be more informative for clinical decisions about 
whether to continue PrEP in pregnancy in light of ongoing risk of HIV infection. A 
recent review indicated no safety reason to withhold PrEP during pregnancy(75) 
and data have demonstrated that HIV risk is increased in pregnancy, highlighting 




Cost-effectiveness studies for PrEP are mainly based on data from the United 
States and suggest that PrEP can be cost-effective and have significant 
budgetary impact, particularly among the highest risk MSM(4, 77-85). Two 
models from the UK concluded that PrEP is cost-effective when targeting the 
highest risk MSM if drug prices are reduced(3, 86) and a study using a third 
model concluded that this would also be the case in the Netherlands(87).   
 
Cost-effectiveness studies are context and epidemic specific and need to 
consider local factors. Key determinants have been found to include HIV 
incidence in the target group being offered PrEP, patient adherence to PrEP, 
levels of condomless sex and numbers of sexual partner. Cost of drug is most 
likely to fall substantially in the upcoming years due to the availability of generic 
formulations and, though partly counter-balanced by decreasing treatment costs, 




In light of the strong evidence for the efficacy of PrEP, PrEP is increasingly being 
incorporated into national HIV prevention guidance, such as in the US(88), 
Europe(89), Kenya, South Africa, and Brazil; Guidelines are being prepared in 
the UK. The WHO guidelines(90) recommend that oral PrEP containing TDF 
should be offered to all people at substantial risk of HIV infection; substantial risk 
is provisionally defined as HIV incidence of approximately 3 per 100 person years 
or greater in the absence of PrEP, although countries might not have accurate 
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incidence data for relevant populations. MSM and TGW in the placebo arms of 
diverse PrEP trials routinely had incidence that exceeded 3.0/100PY, as have 
cohorts of sexually active adolescent girls and young women in Africa.   
 
There are only small differences between these guidelines in terms of drug, 
regimen and eligibility criteria for PrEP. The Center for Disease Control issued 
guidelines in 2014(88) in which they recommended use of daily oral PrEP with 
FTC-TDF for MSM, heterosexual women and men and injecting drug users.   
 
The European AIDS Clinical Society (EACS) guidelines(89) recommends the use 
of oral FTC-TDF for HIV negative MSM and transgender individuals ‘at risk of 
HIV’.  The guidelines define risk as those who are inconsistent in their use of 
condoms with casual partners or with HIV-positive partners who are not on 
treatment.  EACS considers use in HIV-negative heterosexual men and women 
at risk of HIV.  The recommended regimen is daily, but an ‘on demand’ regimen 
as used in the Ipergay trial is also recommended for MSM. 
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Table 3: Summary of published national and international guidelines for PrEP1 




substantial risk of 
acquiring HIV infection 
RECOMMEND 
Any one of: 
HIV positive sexual partner 
Recent bacterial STIa 
High number of sex partners 
History of inconsistent or no 
condom use 
Commercial sex work 
 
(Note does not mention trans-
populations) 
RECOMMEND 
Any one of: 
HIV positive sexual partner 
Recent bacterial STI 
High number of sex partners 
History of inconsistent or no 
condom use 
Commercial sex work 
 
In a high-prevalence area or 
network 
RECOMMEND 
Any one of: 
HIV-positive injecting partner 
Sharing injection equipment 




Offer for people at 
substantial risk of HIV 
infection (provisionally 
defined as >3 per 
100py) 
HIV incidence >3 per 100 py 
 
Includes transgender women 
HIV incidence >3 per 100 person 
years 
 
Includes heterosexual men and 
women with sexual partners with 
undiagnosed or untreated HIV 
where HIV incidence >3 per 100 
person years 
No recommendation made 
EACS 
(2015) 
Use in adults at high 
risk of acquiring HIV 
infection 
RECOMMEND 
Inconsistent in use of condoms 
with casual partners or with HIV-
positive partners who are not on 
treatment. 
 
Recent STI or use of PEPb may 






Inconsistent in use of condoms and 
likely to have HIV –positive partners 
who are not on treatment 
No recommendation made 
ANRS 
(2015) 
Use in adults (aged 
>18) at high risk of 
HIV 
RECOMMEND 
For sexually active MSM at high 
risk of acquiring HIV : 
CONSIDER ON A CASE BY CASE 
BASIS 






Reporting condomless sex with 
at least 2 partners over a 6 
month period 
Having had multiple episodes of 
STIs (syphilis, chlamydia, 
gonococcal infection, primary 
hepatitis B infection or hepatitis 
C infection) in the past year 
Multiple courses of PEP over the 
past year 
Use of psychoactive substances 
during sex in the past year 
Partners of HIV positive people  
who are taking part in trials of 
stopping ARVs 
 
NOT RECOMMENDED FOR: 
Condomless sex that is not 
associated with high risk of 
transmission of HIV 
Other people at high risk of 
acquiring HIV infection: 
Commercial sex worker having 
condomless sex 
Vulnerable individuals having 
condomless sex at high risk of 
transmission of HIV (partner from a 
group with high HIV prevalence- 
multiple sexual partners, from a 
high prevalence country (>1%), 
people who inject drugs, physical 
factors increasing transmission e.g. 
genital or anal ulcer, bleeding) 
Partners of HIV positive people  
who are taking part in trials of 
stopping ARVs 
 
NOT RECOMMENDED FOR: 
condomless sex that is not  
associated with high risk of 
transmission of HIV 
Sex with HIV positive partner who 
is well controlled on antiretroviral 
therapys (VL<50) 





Ongoing high risk of 
acquiring HIV infection 
One or more of: 
One or more HIV positive sexual 
partner, particularly if HIV 
positive partner is not receiving 
stable antiretroviral therapy and 
/or does not have a consistently 
undetectable viral load 
Recent (within last 6 months)STI 
Multiple sex partners 
History of inconsistent or no 
condom use for anal intercourse 
One or more of: 
HIV positive sexual partner(s), 
particularly if HIV positive partner is 
not receiving stable antiretroviral 
therapy and /or does not have a 
consistently undetectable viral load 
Having sexual partners who are 
MSM or use injection drugs 
Sharing injection equipment 
Injecting once or more times per 
day in an unsafe setting (outside 
of safe injection sites) 
Injecting cocaine or 
methamphetamine 
Repeated courses of nPEP 
27 
 




For those at very high 
risk of acquiring HIV 
Condomless anal sex with HIV 
positive or unknown status 
partners 
HIV positive sexual partners with a 





At significant risk of 
acquiring HIV 
Any sexually active HIV-negative 
MSM or transgender person who 
wants PrEP 
Especially: 
HIV positive sexual partner who 
is not confirmed virologically 
supressed 
Partner of unknown HIV status 
Recent STI 
Multiple sexual partners 
History of inconsistent or no 
condom use 
Commercial sex work 
Recurrent PrEP users 
History of sex whilst under the 
influence of alcohol or 
recreational drugs 
 
Especially vulnerable are young 
MSM 
Heterosexual men and women who 
want PrEP, especially: 
HIV positive sexual partner who is 
not confirmed virologically 
supressed 
Partner of unknown HIV status 
Recent STI 
Multiple sexual partners 
History of inconsistent or no 
condom use 
Commercial sex work 
Serodiscordant couples trying to 
conceive 
Recurrent PrEP users 
History of sex whilst under the 
influence of alcohol or recreational 
drugs 
 
Especially vulnerable are 
adolescent girls 
One or more of: 
HIV positive / unknown status 
injecting partner 
Share injecting needles and drug 
preparation equipment 
 
1. Only guidelines published in English and French have been included 





Several alternative drugs and  delivery modalities for PrEP are being investigated 
in animal and human studies. Examples include long-acting preparations, vaginal 
rings and gels, and alternative drug regimens. A search of the AVAC (Global 
Advocacy for HIV Prevention) HIV Prevention Research & Development 
Database (http://www.avac.org/pxrd) which is a comprehensive source of 
information on biomedical HIV prevention clinical trials, found four phase I-III 
trials of PrEP listed as planned and five ongoing phase I-III trials.  These studies 
include oral, long-acting injectable and topical formulations.  There are a large 
number of planned and ongoing demonstration and open label studies. 
 
Three non-oral products have or will be evaluated for efficacy. Tenofovir 
formulated as a vaginal gel and administered before and after sex showed 
modest effectiveness in reducing HIV and herpes simplex virus type 2 in one 
trial(91), and this result was supported by a secondary analysis from an efficacy 
trial assessing daily tenofovir gel(92).  An intravaginal ring releasing the non-
nucleoside reverse transcriptase inhibitor dapivirine showed modest protection in 
two trials(93, 94) and is now being evaluated in open-label studies. The long-
acting integrase inhibitor cabotegravir administered every 2 months as a 3ml 
intramuscular injection is being evaluated in two efficacy trials.  Details of these 
studies  fall outside the scope of this review.   
 
Oral PrEP drug candidates need to have high bioavailablity and/or good 
penetration to the genital mucosa.  A clinical limitation of FTC-TDF PrEP is that 
high plasma concentrations of tenofovir are required to achieve adequate 
intracellular penetration, which can lead to worsening renal impairment in those 
with pre-existing disease.  Tenofovir alafenamide (TAF) has greater intracellular 
bioavailability, and it has been shown that lower doses can be used to achieve 
the same therapeutic benefit when used for HIV treatment, with less risk of 
impact on renal function or bone mineral density. The effectiveness of TAF 
combined with FTC is currently being evaluated in the DISCOVER trial(95). 
 
Another candidate is Maraviroc, a CCR5 inhibitor,  which was investigated for 
safety and acceptability in the NEXT-PrEP/HPTN 069 study(96). Maraviroc has 
few  known side effects and a resistance profile that does not overlap with 
commonly used treatments for HIV. In the NEXT-PrEP study, maraviroc was 
given alone or in combination with emtricitabine or with TDF, with FTC-TDF as a 
control. Explant data from the NEXT-PrEP study demonstrated higher levels of 
HIV replication in rectal tissue from the Maraviroc group compared to those 
treated with Maraviroc paired with another antiretroviral(97).  There were also two 
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seroconversions in the Maraviroc group in spite of high levels of drug in the  
tissue. These preliminary data are not encouraging and there are not thought to 
be current plans to develop maraviroc as a PrEP agent. 
 
Many other HIV prevention modalities under investigation, including  a preventive 
HIV vaccine and the use of monoclonal antibodies.  These are outlined in figure 
4, but  fall outside the scope of this review. 
 
Combination prevention strategies 
It has long been argued that a successful public health strategy to prevent HIV 
requires a combination approach because of the complexities involved, and 
modelling studies support the idea that such an approach is essential to eliminate 
HIV(98-100).  Therefore, PrEP is not being thought of in isolation, and studies are 
underway to explore what the optimal prevention packages might look like, 
including behavioural risk reduction strategies and treatment as prevention 
alongside PrEP. (see figure 3). 
 
Fig 3: Potential impact of expanded HIV testing, treatment and PrEP in the 













This review provides a comprehensive overview of PrEP, including information 
and discussion on cost-effectiveness, guidelines and breakthrough infections.  
The PROUD and IPERGAY studies in particular, which were not included in 
depth in the Fonner review and are discussed in detail in this review, enhance 
our understanding of the efficacy  of PrEP and adherence among high-risk MSM.   
 
It is clear from the evidence available that oral FTC-TDF PrEP is highly effective 
in reducing the risk of HIV acquisition across different types of sexual exposure, 
genders, dosing schedules, and different country contexts and epidemics.  While 
only one small trial has assessed TDF monotherapy in MSM, there is high quality 
evidence for the effectiveness of TDF in reducing heterosexual transmission, 
contrary to the common misconception that PrEP is not effective among 
heterosexual women. Only one trial has been conducted in PWID; although it 
demonstrated effectiveness in HIV prevention, it has not been possible to 
separate the reduction in the risk of sexual acquisition from the possible effect on 
reducing intravenous blood borne transmission. An oral event based regimen has 
only been evaluated in MSM, and pharmacokinetic studies have demonstrated 
that drug concentrations of TDF are higher in rectal than vaginal tissue. 





Oral FTC-TDF PrEP has been shown to be extremely safe with minimal impact 
on kidney, bone or pregnancy outcomes, and there is no evidence that the 
effectiveness of PrEP has been diminished by risk compensation during open-
label and programmatic follow-up. However, it remains too early to assess the 
impact of PrEP rollout on STI incidence at a population level, and any changes in 
STI incidences will be difficult to disentangle from temporal increases in STIs in 
the wider population. 
  
Lots of challenges remain.  Access to PrEP is still limited and there are 
disparities by race and gender. Different pricing and access models for PrEP 
need to be explored to avert further widening of these inequalities. Adherence is 
essential for PrEP to be effective and research is already being conducted to 
understand how to optimise adherence, including through use of mobile 
technology. The optimal combination prevention programme needs to be defined, 
but this will depend on local epidemiology, service provision and cost-
effectiveness measures.   
 
Cost-effectiveness studies have highlighted that scale up of PrEP is challenging 
in countries that have to pay the full price for the branded drug.  Roll out is likely 
to be particularly challenging where there is lack the infrastructure for regular HIV 
and STI screening. The drugs were licensed for use as PrEP five years ago, and 
an increasing number of countries are embarking on national programmes, with 
others having approved reimbursement of PrEP. However, coverage is not 
universal within  many countries and key groups may not be accessing PrEP due 
to barriers such as cost, knowledge and stigma(101, 102). 
 
San Francisco’s experience has shown that early adoption of PrEP can be slow, 
but also that subsequent rapid uptake can have a substantial impact on HIV 
incidence.  Although there are residual programmatic questions about eligibility, 
uptake and duration of use it is clear that in countries where there is access to 
PrEP, clinicians have a duty of care to inform those at risk of acquiring HIV about 
the benefits of PrEP. Healthcare  providers’ knowledge of PrEP is variable(103).  
The successes of San Francisco and London may reflect local awareness of, and 
prioritization and investment in PrEP.  Policymakers need to be aware of local 
PrEP policies and provide training for clinicians who are involved in PrEP care to 
ensure that access to PrEP is fair and equitable and that structural barriers to 






1. What does the inclusion of PrEP in the wider HIV prevention strategy add 
to the impact on HIV incidence at a population level? 
2. Will there be an impact on STI incidence and antiretroviral resistance at a 
population level?  
3. How can we target PrEP most appropriately to attain optimal population 
level impact at a manageable cost? 
4. Are there better alternatives to coformulated tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC) PrEP? 
5. What strategies can be used to maximise the adherence to PrEP? 
6. In epidemics where HIV incidence is declining, is there a point at which 
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